Business
LEVBIO: Q3 2025 saw 5% revenue growth, higher margins, and improved cash flow amid Nordic expansion
LEVBIO: Q3 2025 saw 5% revenue growth, higher margins, and improved cash flow amid Nordic expansion
About this update from Level Bio Ab
Revenue grew 5% year-over-year in Q3 2025, with gross margin rising to 57% and net loss narrowing. Strong order intake and positive cash flow signal improved performance, while expansion in the Nordics and stable recurring revenues support a positive outlook.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.